# OCUL Stock Faces NDA Catalyst Test

> Ocular Therapeutix's Q4 2026 NDA submission could reshape wet AMD treatment if FDA accepts its 505(b)(2) pathway.
- Title: OCUL Stock Faces NDA Catalyst Test | Shortify
- Summary: Ocular Therapeutix's Q4 2026 NDA submission could reshape wet AMD treatment if FDA accepts its 505(b)(2) pathway. FDA acceptance of Ocular's NDA by Q4 2026…
- Keywords: ocular therapeutix, nda, ocul, pharmaceuticals, 505b2, wet amd, sol-1 trial, sol-r trial, fda, Stock, Faces, Catalyst
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/is-ocular-therapeutix-ocul-stock-a-buy-ahead-of-its-major-nda-catalyst
- Author: Newsdesk
- Published: 2026-09-23T17:47:26+00:00
- Read time: 1 min
- Topics: ocular therapeutix, nda, ocul, pharmaceuticals, 505b2, wet amd, sol-1 trial, sol-r trial, fda
## Q2 2026 Earnings Beat
Ocular Therapeutix reported $13.48 million revenue, beating analyst estimates by 5.3%.
## AXPAXLI Clinical Breakthrough
AXPAXLI showed 72% less treatment burden for wet AMD patients compared to aflibercept.
## NDA Submission Timeline
Ocular plans FDA NDA submission in Q4 2026 after Q3 2026 pre-NDA meeting.
## 505(b)(2) Pathway Advantage
FDA's 505(b)(2) pathway could speed up review by 60 days using existing safety data.
## Q2 2026 Financials
Ocular reported a $0.35 GAAP loss per share, beating estimates by 11.2%.
## Cash Runway
Company has $598.6 million cash as of June 30, 2026, sufficient through 2028.
## SOL-R Trial Readout
SOL-R Phase 3 trial topline results expected in Q1 2027 to confirm AXPAXLI's efficacy.
## Market Competition
Wet AMD market dominated by established anti-VEGF therapies with high cost sensitivity.
## Investor Catalyst
Q4 2026 NDA submission is the primary catalyst for stock performance.
## Key takeaway

FDA acceptance of Ocular's NDA by Q4 2026 is critical for stock performance.